Changes of Structure and Enzyme Activity in Malabsorption during Gastrointestinal Paresis

Póka, L; Czirbusz, G; Földi, E.; Farkas, A.; Kerner, John A.; Bartek, I

doi:10.1159/000196830

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, malabsorption syndromes can pertain to those which can affect the absorption of drugs and nutrients, may be drug-induced, or both. The main GI factors recognised for their involvement in drug malabsorption are numerous, ranging from available anatomical surface area to enzyme activity (Poka et al, 1968); changes to microbiota (Mortimer et al, 1964); food presence (Varum et al, 2013b); motility; intestinal and gallbladder obstruction (Collins et al, 1978;Parsons, 1977); pancreatitis (Dimagno et al, 1973); post-surgical causes and inflammatory disorders (Vitek, 2015). Drug and nutrient malabsorption is also a common consequence of surgical procedures and/or resections involving the stomach and small intestine, associated with anatomical changes including reduced surface area, peristalsis, transit time and gut wall metabolism (Titus et al, 2013), and will be discussed later in the review.…”

Section: Malabsorption Syndromesmentioning

confidence: 99%

All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance

Hatton

Madla

Rabbie

et al. 2018

International Journal of Pharmaceutics

View full text Add to dashboard Cite

The term "disease" conjures a plethora of graphic imagery for many, and the use of drugs to combat symptoms and treat underlying pathology is at the core of modern medicine. However, the effects of the various gastrointestinal diseases, infections, co-morbidities and the impact of gastrointestinal surgery on the pharmacokinetic and pharmacodynamic behaviour of drugs have been largely overlooked. The better elucidation of disease pathology and the role of underlying cellular and molecular mechanisms have increased our knowledge as far as diagnoses and prognoses are concerned. In addition, the recent advances in our understanding of the intestinal microbiome have linked the composition and function of gut microbiota to disease predisposition and development. This knowledge, however, applies less so in the context of drug absorption and distribution for orally administered dosage forms. Here, we revisit and re-evaluate the influence of a portfolio of gastrointestinal diseases and surgical effects on the functionality of the gastrointestinal tract, their implications for drug delivery and attempt to uncover significant links for clinical practice.

show abstract